DeepHealth has announced its acquisition of UK-based Kheiron Medical Technologies, marking a significant consolidation in the AI-powered breast cancer screening space. The acquisition brings together DeepHealth’s Smart Mammo platform with Kheiron’s Mia (Mammography Intelligent Assessment) suite of solutions.
The move appears strategically timed as AI continues to gain traction in medical imaging, particularly in mammography where radiologist shortages and increasing screening volumes are creating significant workflow challenges.
Kheiron, founded in 2016 and headquartered in London, has made notable progress in clinical validation. The company’s Mia technology achieved a significant milestone as the first AI solution to undergo prospective evaluation in EU and UK breast screening programs, where it demonstrated it could deliver double-reading quality with a single human reader. This capability complements DeepHealth’s existing Smart Mammo platform, which has already shown success in high-volume screening programs, including RadNet’s Enhanced Breast Cancer Detection (EBCD) program in the United States.
“Finding cancer in its earliest stages gives patients a greater chance of survival. At DeepHealth, we are passionate about the meaningful role we can play in cancer detection. The acquisition of Kheiron will further expand our portfolio of AI-powered diagnostic and screening solutions, enabling us to accelerate the introduction of our breast cancer solutions in Europe,” said Sham Sokka, PhD, Chief Operating and Technology Officer DeepHealth.
The combination appears particularly significant for the European market. According to the European Commission Initiative on Breast Cancer guidelines, double reading of mammograms is recommended as standard practice across European breast screening programs. This approach, where two radiologists independently review each mammogram, has been shown to increase cancer detection rates but also requires significant radiologist resources. In this context, Kheiron’s validated AI solution, which can deliver double-reading quality with a single human reader, could prove especially valuable.
“Our mission to improve breast cancer outcomes has always been a global one. As part of DeepHealth, we will be able to give many more women a better fighting chance against breast cancer,” said Peter Kecskemethy, Kheiron’s co-founder. “Together, we will be even better positioned to equip radiologists with the tools they need to detect even the most subtle lesions and further optimize breast cancer screening.”
This acquisition signals growing maturity in the AI mammography space, where we’re seeing increased consolidation as companies seek to build comprehensive screening solutions that can serve different regulatory and clinical environments.
